NASDAQ:TECH - BIO-TECHNE Stock Price, Price Target & More

BIO-TECHNE trades on the NASDAQ under the ticker symbol "TECH."

BIO-TECHNE declared a quarterly dividend on Thursday, May 3rd. Shareholders of record on Monday, May 14th will be given a dividend of $0.32 per share on Friday, May 25th. This represents a $1.28 annualized dividend and a yield of 0.82%. The ex-dividend date of this dividend is Friday, May 11th. View BIO-TECHNE's Dividend History.

BIO-TECHNE Corp (NASDAQ:TECH) released its earnings results on Wednesday, May, 2nd. The biotechnology company reported $1.21 EPS for the quarter, beating analysts' consensus estimates of $1.14 by $0.07. The biotechnology company had revenue of $164 million for the quarter, compared to analysts' expectations of $163.43 million. BIO-TECHNE had a net margin of 18.29% and a return on equity of 14.75%. BIO-TECHNE's quarterly revenue was up 13.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.97 earnings per share. View BIO-TECHNE's Earnings History.

BIO-TECHNE is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for BIO-TECHNE.

6 equities research analysts have issued 1 year target prices for BIO-TECHNE's shares. Their forecasts range from $115.00 to $185.00. On average, they anticipate BIO-TECHNE's stock price to reach $157.00 in the next twelve months. This suggests a possible upside of 0.4% from the stock's current price. View Analyst Ratings for BIO-TECHNE.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIO-TECHNE in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to BIO-TECHNE include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Qiagen (QGEN), AveXis (AVXS), Ablynx (ABLYF), China Biologic Products (CBPO), Spark Therapeutics (ONCE), argenx (ARGX), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), Regenxbio (RGNX) and Momenta Pharmaceuticals (MNTA).

News stories about TECH stock have been trending somewhat positive this week, according to Accern. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BIO-TECHNE earned a media sentiment score of 0.11 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 45.11 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

BIO-TECHNE's stock is owned by many different of retail and institutional investors. Top institutional investors include Riverbridge Partners LLC (1.37%), Fred Alger Management Inc. (1.33%), Conestoga Capital Advisors LLC (0.72%), Summit Creek Advisors LLC (0.29%), Confluence Investment Management LLC (0.08%) and First National Bank of Omaha (0.07%). Company insiders that own BIO-TECHNE stock include Charles A Dinarello, Charles R Kummeth, John L Higgins, Karen A Holbrook, Kevin S Gould, Robert V Baumgartner and Roger C Lucas. View Institutional Ownership Trends for BIO-TECHNE.

TECH stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Summit Creek Advisors LLC, Municipal Employees Retirement System of Michigan, First National Bank of Omaha, Foundry Partners LLC, Bremer Trust National Association, Huntington National Bank and State of Alaska Department of Revenue. Company insiders that have sold BIO-TECHNE company stock in the last year include Charles A Dinarello, Charles R Kummeth, Karen A Holbrook, Robert V Baumgartner and Roger C Lucas. View Insider Buying and Selling for BIO-TECHNE.

TECH stock was purchased by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., Bank of Montreal Can, Nisa Investment Advisors LLC, Conestoga Capital Advisors LLC, Affiance Financial LLC, Pendal Group Ltd, Wendell David Associates Inc. and Contravisory Investment Management Inc.. View Insider Buying and Selling for BIO-TECHNE.

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of TECH stock can currently be purchased for approximately $156.42.

BIO-TECHNE has a market capitalization of $5.78 billion and generates $563 million in revenue each year. The biotechnology company earns $76.08 million in net income (profit) each year or $3.42 on an earnings per share basis. BIO-TECHNE employs 1,800 workers across the globe.

BIO-TECHNE's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]